Brindle L A
University of Southampton, Southampton, UK.
Eur J Cancer Care (Engl). 2017 May;26(3). doi: 10.1111/ecc.12699. Epub 2017 May 10.
As possibilities for the early detection of indolent cancers, and precursors to cancer, multiply, GPs will increasingly be involved in discussions with patients about risks and benefits of early diagnosis and treatment. Over time, improvements in evidence may decrease uncertainty about outcomes for patients and clinicians. However, where survival benefits are small, or uncertain, or risks are unacceptable to patients, grounds for preference-sensitive decision-making will remain. How risks and benefits of early detection, and the significance of indolent or low risk cancers, are communicated, will be key, if overtreatment and overdiagnosis are to be avoided.
随着惰性癌症及癌症前体早期检测可能性的增加,全科医生将越来越多地参与到与患者关于早期诊断和治疗的风险与益处的讨论中。随着时间推移,证据的改善可能会减少患者和临床医生对治疗结果的不确定性。然而,在生存获益微小、不确定或风险不为患者所接受的情况下,偏好敏感型决策的依据将依然存在。若要避免过度治疗和过度诊断,如何传达早期检测的风险与益处以及惰性或低风险癌症的意义将是关键。